ClinicalTrials.gg
CompletedNCT07440108Updated May 22, 2026

Evaluation of a Biopsychosocial System

An observational study in T1D, Type 1 Diabetes (T1D) and Type 1 Diabetes, sponsored by Adhera Health, Inc.. Completed at 1 site in Spain. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by Adhera Health, Inc. · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 150 studies in Diabetes Mellitus, Type 1 with a site in Spain — 25 open to participants now, 30 under way, 5 of them phase 3. Diabetes Mellitus, Type 1 · Spain.

Enrollment
31st of 36
30 · median 170
Started
2025
with 17 others
Observational
36 of 150
8 open now
Registered
138th of 150
by date
Lead sponsor
4 of 150
Adhera Health, Inc.

Among the 150 studies in Diabetes Mellitus, Type 1 with a site in Spain, this one is the 31st largest by enrollment of the 36 observational ones that give a count, is one of 18 that started in 2025, is one of 36 observational ones, and was the 138th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

25 of the 150 studies in Diabetes Mellitus, Type 1 with a site in Spain are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 150 studies in Diabetes Mellitus, Type 1 with a site in Spain, or all of them as a file.
02

Study summary

The goal of this observational study is to evaluate the feasibility of a biopsychosocial sensing system integrated into the Adhera Caring Digital Program® for caregivers of children with type 1 diabetes (T1D). The main questions it aims to answer are:

  • Is the integrated biopsychosocial sensing system feasible to use in real-world conditions over a 2-month period?
  • Is the system usable and acceptable for caregivers?
  • How do biopsychosocial factors interact with severe glucose events, and what do these dynamics reveal about caregiver distress during T1D management?

Findings from this study will help determine whether the system can support future development of data-driven interventions for families managing pediatric T1D.

03

Conditions studied

  • T1D
  • Type 1 Diabetes (T1D)
  • Type 1 Diabetes

Keywords

  • Type 1 Diabetes
  • T1D
  • mhealth
  • caregiver
  • CAT
  • EMA
  • CGM
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study population consists of caregivers of children with type 1 diabetes recruited from Hospital Miguel Servet in Spain. Eligible caregivers are adults who serve as the primary caregiver for a child under 18 years old with a confirmed diagnosis of T1D and who uses the FreeStyle Libre 2 continuous glucose monitoring system. Families must be willing to share the child's CGM data and have experienced at least two severe glucose events in the previous month. Caregivers must own a compatible smartphone and be able to use a mobile sensing system. Exclusion criteria include significant cognitive or physical impairments, inability to read or understand Spanish, or participation in other clinical trials involving psychological or diabetes-related interventions.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Caregivers aged ≥18 years who are the primary caregivers of a child with T1D.
  • The child should be younger than 18 years with a confirmed diagnosis of T1D and currently using CGM, specifically Free-Style Libre 2.
  • The family should be willing to share their child's CGM data with the Adhera Caring Digital Program®, as well as retrospective CGM data from the previous 2 months prior to joining the study.
  • The child should have had at least 2 severe glycemic events in the previous month, either hyperglycemic (>250 mg/dL for more than 2 hours) or hypoglycemic (\<70 mg/dL for more than 15 min). This will be assessed by their pediatric endocrinologist during recruitment.
  • Caregivers must own a smartphone compatible with the study app.
  • Willingness and ability to use a smartphone-based sensing system.

Exclusion criteria

Exclusion criteria:

  • Caregivers with significant cognitive or physical impairments preventing study participation.
  • Inability to read or understand the Spanish language.
  • Participation in other clinical trials involving psychological or diabetes management interventions.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (actual)
Patient registry
No

Groups and cohorts

  • Primary caregivers of a child with T1D

    This cohort includes caregivers of children with type 1 diabetes who will use the biopsychosocial sensing system integrated into the Adhera Caring Digital Program® for 2 months. No interventions are administered; caregivers use the system as part of this observational feasibility study.

    Other: Use of Biopsychosocial Sensing System

Interventions

  • OtherUse of Biopsychosocial Sensing System

    Participants use a biopsychosocial sensing system integrated into the Adhera Caring Digital Program® for a 2-month period. The system collects caregiver emotional well-being data through computer adaptive testing (CAT) and ecological momentary assessment (EMA), along with children's CGM data. This is an observational study and no treatment or behavioral intervention is administered.

06

What researchers measure

Primary outcomes

  1. Feasibility of the Biopsychosocial Sensing System

    Feasibility will be assessed using metrics from the Adhera Caring Digital Program®, including: \- Response rate to Ecological Momentary Assessment (EMA) prompts

    Time frame: From enrollment to the end of study at month 2

  2. Feasibility of the Biopsychosocial Sensing System

    Feasibility will be assessed using metrics from the Adhera Caring Digital Program®, including: \- Completion rates of scheduled CAT assessments

    Time frame: From enrollment to the end of study at month 2

Secondary outcomes

  1. Usability and acceptability of the system

    Outcome Measure: System Usability Scale (SUS) score. Unit of Measure: SUS score (0-100, higher scores indicate better usability). Description: The System Usability Scale is a 10-item scale based on a 5-point Likert scale assessing perceived usability.

    Time frame: At the end of the study (Month 2)

  2. Caregiver Distress Measured by Ecological Momentary Assessment (EMA)

    Caregiver distress will be measured using Ecological Momentary Assessment (EMA) delivered via smartphone. Distress will be quantified using EMA distress scores reported in response to daily prompts. Unit of Measure: EMA distress score (continuous scale)

    Time frame: From enrollment to the end of the study at month 2

  3. Caregiver Distress Measured by Computer Adaptive Testing (CAT)

    Caregiver distress will be assessed using Computer Adaptive Testing (CAT) administered electronically. Distress will be quantified using CAT-generated distress scores. Unit of Measure: CAT distress score (continuous scale)

    Time frame: From enrollment to the end of the study at month 2

  4. Psychosocial Patterns and Caregiver Responses to Glucose Events - Caregiver Distress (Parent Diabetes Distress Scale)

    Caregiver distress will be measured using the Parent Diabetes Distress Scale (Parent-DDS), a 20-item questionnaire assessing four subscales: * Personal distress * Teen management distress * Parent/teen relationship distress * Healthcare team distress Scoring: For each scale and the total score, responses are summed and divided by the number of items in that scale, yielding a mean item score ranging from 0 to 5. Interpretation of scores: * -1.9: Little or no distress * 2.0-2.9: Moderate distress * ≥3.0: High distress Higher scores indicate greater caregiver distress. Associations between Parent-DDS scores (total and subscale scores) and children's severe glucose events (hyperglycemia \>250 mg/dL for \>2 hours or hypoglycemia \<70 mg/dL for \>15 minutes) will be analyzed. Clinicians may consider moderate or high distress worthy of clinical attention depending on context.

    Time frame: From enrollment to the end of the study at month 2

  5. Mobile Application Engagement

    Engagement will be quantified using app logs and user profiling, including frequency and duration of interactions with the Adhera Caring Digital Program®.

    Time frame: From enrollment to the end of study at month 2

  6. Frequency of Severe Glucose Events in Children

    Outcome Measure Description Severe glucose events will be defined as hyperglycemia \>250 mg/dL for more than 2 hours or hypoglycemia \<70 mg/dL for more than 15 minutes, as measured by continuous glucose monitoring. Unit of Measure Number of severe glucose events. Higher number, worse outcome

    Time frame: From enrollment to the end of the study at month 2

07

Study locations

1 site
  • Hospital Universitario Miguel Servet
    Zaragoza, Aragon 50009, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2025 to primary completion in Jan 2026, 2 months.

Of 50 industry-sponsored observational studies under Diabetes Mellitus, Type 1, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's 2 months is below that.

Counting every sponsor, half of 298 studies reached it within 28 months; a quarter within 12 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2025
First posted
Feb 27, 2026
StartActual
Nov 24, 2025
Primary completionActual
Jan 26, 2026
CompletionActual
Mar 30, 2026
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07440108
Lead sponsor
Adhera Health, Inc.
Collaborators
Hospital Universitario Miguel Servet, Zaragoza
Responsible party
Sponsor
First posted
Feb 27, 2026
Start date
Nov 24, 2025
Primary completion
Jan 26, 2026
Completion
Mar 30, 2026
Last update
May 22, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion